Drug O and drug K have the same mechanism of action, both are targeted drugs used in tumor therapy, and they are highly consistent in their mechanism of action, the difference lies in the different range of cancer types treated by the two drugs. drug O is applicable to a wider range of cancer types than drug K, and the specific usage of the two drugs is very complicated, so you should ask your doctor’s opinion. Both drugs work by inhibiting the PD-1 receptor in T-cells; drug O is nabulizumab, short for OPDIVO; drug K is pembrolizumab, short for KEYTRUDA. Navulizumab is indicated for the treatment of adult patients with selected non-small cell carcinomas, patients with squamous cell carcinomas that have progressed after platinum-based therapy, and adenocarcinomas of the stomach or gastroesophageal junction. Pembrolizumab is indicated for the treatment of certain recurrent or metastatic cervical cancer, colon cancer, gastric cancer, squamous cell carcinoma of the head and neck, classic Hodgkin’s lymphoma, and liver cancer. Please strictly follow the doctor’s instructions for drug treatment, and do not use the drug by yourself.